CYTOF — Altamira Therapeutics Share News
0.000.00%
Last trade - 00:00Altamira up on nasal spray re-launch in Europe
Brief: Altamira Therapeutics Re-Launches Bentrio In Europe For Allergic Rhinitis
Brief: Altamira Therapeutics Completes Enrollment For COVAMID Trial With Bentrio In Acute COVID-19
Altamira rises on plans for RNA business, nasal spray
Brief: Altamira Therapeutics Says Progressing With Plans To Focus On RNA Business
Brief: Altamira Therapeutics Completes Interim Sample Size Analysis Of Covamid Trial With Bentrio
Brief: Altamira Therapeutics To Develop Novel Generation Of Rheumatoid Arthritis Therapeutics Based On Its Proprietary Oligophore Delivery Platform And SiRNA Targeting Key Inflammation Checkpoint
Altamira's cancer treatment shows promise, shares soar
Brief: Altamira Says SemaPhore Platform Shown Effective In Intracellular mRNA Delivery For Cancer Therapy
U.S. STOCKS ON THE MOVE-Virgin Orbit, ETSY, Coinbase, Peloton
U.S. STOCKS ON THE MOVE-Robinhood, Spirit Airlines, Polestar, Axsome Therapeutics
Brief: Altamira Therapeutics Ltd Receives FDA 510(K) Clearance For Bentrio To Treat Allergic Rhinitis
Brief: Altamira Therapeutics Files Prospectus Relates To Disposition From Time To Time Of Up To 2.8 Mln Common Shares By Selling Shareholder
U.S. STOCKS ON THE MOVE-Carnival Corp, Insignia Systems, Scienjoy
Brief: Altamira Therapeutics Files For Mixed Shelf Of Up To $79.2 Mln
Brief: Auris Medical To Develop Kras-Targeting Rna Treatment For Colorectal Cancer As First Therapeutic Indication For Oligophore™ Technology
Brief: Auris Medical To Initiate Market Launch Of Bentrio Nasal Spray In Germany
Auris Medical: Rises on positive data from tumor-inhibition animal study
Brief: Auris Medical Announces Significant Inhibition Of Tumor Growth With Oligophore Sirna Targeting Nf-Κb In Murine Model Of Adult T-Cell Leukemia / Lymphoma